Shaji Kumar, MD, and Prashant Kapoor, MD, on BCL2 Inhibition for the Treatment of Resistant Multiple Myeloma

Posted: Tuesday, July 28, 2020

Shaji Kumar, MD, and Prashant Kapoor, MD, both of the Mayo Clinic, discuss updated results from two abstracts on venetoclax in relapsed or refractory multiple myeloma: the phase III BELLINI trial of venetoclax or placebo in combination with bortezomib and dexamethasone; and a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, with or without bortezomib.